Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Silica is a proven and highly effective anti-caking agent that has been used for decades
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
The inspection conducted by EDQM at its Visakhapatnam facility
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
This approval reflects company’s unwavering commitment that the quality assurance
Subscribe To Our Newsletter & Stay Updated